Lack of Braf V600e protein expression in primary central nervous system lymphoma

Mutations in the v-raf murine sarcoma viral oncogenes homolog B1 (BRAF), most commonly of the V600E type, are present in a variety of human malignancies including malignant melanoma, papillary thyroid cancers, and hairy-cell leukemia and specific therapeutically active BRAF inhibitors exist. We aime...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bergmeister-Berghoff, Anna Sophie (VerfasserIn) , Capper, David (VerfasserIn) , Preusser, Matthias (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2013/07/01
In: Applied immunohistochemistry & molecular morphology
Year: 2013, Jahrgang: 21, Heft: 4, Pages: 351-353
ISSN:1533-4058
DOI:10.1097/PAI.0b013e3182688e59
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1097/PAI.0b013e3182688e59
Verlag, Volltext: https://insights.ovid.com/pubmed?pmid=23235345
Volltext
Verfasserangaben:Anna S. Berghoff, David Capper, Matthias Preusser
Beschreibung
Zusammenfassung:Mutations in the v-raf murine sarcoma viral oncogenes homolog B1 (BRAF), most commonly of the V600E type, are present in a variety of human malignancies including malignant melanoma, papillary thyroid cancers, and hairy-cell leukemia and specific therapeutically active BRAF inhibitors exist. We aimed to investigate BRAF V600E protein expression in primary central nervous system lymphoma (PCNSL). We investigated BRAF V600E expression in formalin-fixed and paraffin-embedded surgical tissue specimens of 20 immunocompetent patients with PCNSL using the mutation-specific monoclonal mouse antibody VE1. Ten male and 10 female patients with a median age of 60 years (range, 44 to 71 y) at time of operation were included. All cases were qualified as diffuse large B-cell lymphomas. None of the investigated cases demonstrated specific immunoreactivity for BRAF V600E mutation. Our data provide evidence that the BRAF V600E mutation is not pathobiologically relevant in PCNSL and as a consequence is not a feasible drug target in this tumor type.
Beschreibung:Gesehen am 07.05.2018
Beschreibung:Online Resource
ISSN:1533-4058
DOI:10.1097/PAI.0b013e3182688e59